Ansofaxine hydrochloride vs Liafensine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: Serotonin/norepinephrine/dopamine transporter · full Major Depressive Disorder pipeline
Ansofaxine hydrochloride
Marketed by Luye Pharma Group
NCT04853407 · Phase 3 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 558 patients and a validated depression-severity scale as the primary endpoint. Both ansofaxine doses significantly outperformed placebo (MADRS reductions of 20.0 and 19.9 points versus 14.6 with placebo, p<0.0001).
Next expected readout: February 2027 · NCT06426485 (registry estimate)
Reported efficacy
Montgomery- Åsberg Depression Rating Scale(MADRS) (8 Weeks): MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001). (met)
Result source: NCT04853407
Liafensine
Developed by Denovo Biopharma and partners
NCT05113771 · Phase 2 · completed
The study randomized 197 participants to two liafensine doses or placebo, with participants and investigators blinded to treatment. Its primary clinical endpoint, change in MADRS score at Day 42 in DGM4-positive patients, favored combined liafensine over placebo with statistical significance, supporting a strong evidence grade.
Reported efficacy
Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31) (met)
Result source: NCT05113771
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ansofaxine hydrochloride | Liafensine |
|---|---|---|
| MADRS, change (acute) | -19.9 vs -14.6a−5.3 vs placeboNCT048534071 other result
| -15.5 vs -11−4.5 vs placeboNCT051137711 other result
|
| CGI-S, change (acute) | —Not posted · NCT04853407 | -1.5 vs -1.1−0.4 vs placeboNCT051137711 other result
|
| MADRS response | —Not posted · NCT04853407 | —Not reported |
| MADRS remission | —Not posted · NCT04853407 | —Not reported |
| Relapse (% of patients) | —Not posted · NCT04853407 | —Not reported |
MADRS, change (acute)
- Ansofaxine hydrochloride
- -19.9 vs -14.6a−5.3 vs placeboNCT04853407
1 other result
- -20 vs -14.6 NCT04853407
- Liafensine
- -15.5 vs -11−4.5 vs placeboNCT05113771
1 other result
- -15.4 vs -11 NCT05113771
CGI-S, change (acute)
- Ansofaxine hydrochloride
- —Not posted · NCT04853407
- Liafensine
- -1.5 vs -1.1−0.4 vs placeboNCT05113771
1 other result
- -1.5 vs -1.1 NCT05113771
MADRS response
- Ansofaxine hydrochloride
- —Not posted · NCT04853407
- Liafensine
- —Not reported
MADRS remission
- Ansofaxine hydrochloride
- —Not posted · NCT04853407
- Liafensine
- —Not reported
Relapse (% of patients)
- Ansofaxine hydrochloride
- —Not posted · NCT04853407
- Liafensine
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ansofaxine hydrochloride: 0 of 4 rows · Liafensine: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ansofaxine hydrochloride | Liafensine |
|---|---|---|
| Dropout rate | — | 24.6%2mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 show 1 more result6.2%1mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 |
| Discontinued due to AEs | — | —2mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 show 1 more result—1mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 |
| Serious AEs | — | 4.7%2mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 show 1 more result0%1mg NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 |
| Most frequent reported AEs | — | 2mg headach 21.9% (placebo 22.4%) constipation 9.4% (placebo 0%) decreased appetite 9.4% (placebo 3%) NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 show 1 more result1mg headach 30.8% (placebo 22.4%) nausea 16.9% (placebo 10.4%) dizziness 12.3% (placebo 7.5%) NCT05113771 · Phase 2 · monotherapy · Major Depressive Disorder, Treatment-Resistant Depression · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liafensine
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ansofaxine hydrochloride's landscape · Liafensine's landscape